Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Debio 4126 versus placebo and open-label Debio 4126 in previously somatostatin analog-treated acromegaly
2024-516616-24-00Phase 3Authorised
- Sponsor
- Debiopharm
- Start
- Jul 2025
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of Debio 4126 in acromegaly (3 arms), sponsored by Debiopharm. Primary endpoint: Percentage of participants with IGF-1 less than or equal to 1 times the upper limit of normal at Week 36. Planned start Jul 2025; status: authorised.
02
Drugs
Debio 4126
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2024-516616-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516616-24-00.